BACKGROUND: Antisocial personality disorder (ASPD) is a psychiatric disorder characterized by a long-term pattern of manipulating, exploiting, or violating the rights of others. METHODS: Subjects ascertained for genetic studies of substance dependence (SD) and diagnosed with ASPD and comorbid SD were included in a two-stage genetic association study. In the discovery stage, 627 single nucleotide polymorphisms (SNPs) located in 179 candidate genes for addiction were analyzed in a case-control cohort and family-based cohort. The significant findings were replicated in an independent case-control cohort. RESULTS: One SNP, rs13134663, in the collagen XXV alpha 1 gene (COL25A1) was significantly associated with ASPD in both African Americans and European Americans (smallest p values were .0002 and .0004, respectively). There was also evidence of association with the same SNP in independent samples of African American and European American cases and control subjects (p = .035 and .033, respectively). Analysis of the combined set of case-control subjects yielded an allelic p value of 9 × 10(-6) with odds ratio (95% confidence interval) of 1.3 (1.16, 1.47) (smallest p = 1 × 10(-7); Bonferroni threshold p = .00012). CONCLUSIONS: The COL25A1 gene, located at chromosome 4q25, encodes the collagen-like Alzheimer amyloid plaque component precursor, a type II transmembrane protein specifically expressed in neurons; it co-localizes with amyloid β in senile plaques in Alzheimer disease brains. This SNP maps to the transcription factor binding site and is conserved in 17 vertebrates, including mice and rats. Our findings suggest that COL25A1 may be associated with ASPD, especially in the context of SD.
BACKGROUND:Antisocial personality disorder (ASPD) is a psychiatric disorder characterized by a long-term pattern of manipulating, exploiting, or violating the rights of others. METHODS: Subjects ascertained for genetic studies of substance dependence (SD) and diagnosed with ASPD and comorbid SD were included in a two-stage genetic association study. In the discovery stage, 627 single nucleotide polymorphisms (SNPs) located in 179 candidate genes for addiction were analyzed in a case-control cohort and family-based cohort. The significant findings were replicated in an independent case-control cohort. RESULTS: One SNP, rs13134663, in the collagen XXV alpha 1 gene (COL25A1) was significantly associated with ASPD in both African Americans and European Americans (smallest p values were .0002 and .0004, respectively). There was also evidence of association with the same SNP in independent samples of African American and European American cases and control subjects (p = .035 and .033, respectively). Analysis of the combined set of case-control subjects yielded an allelic p value of 9 × 10(-6) with odds ratio (95% confidence interval) of 1.3 (1.16, 1.47) (smallest p = 1 × 10(-7); Bonferroni threshold p = .00012). CONCLUSIONS: The COL25A1 gene, located at chromosome 4q25, encodes the collagen-like Alzheimer amyloid plaque component precursor, a type II transmembrane protein specifically expressed in neurons; it co-localizes with amyloid β in senile plaques in Alzheimer disease brains. This SNP maps to the transcription factor binding site and is conserved in 17 vertebrates, including mice and rats. Our findings suggest that COL25A1 may be associated with ASPD, especially in the context of SD.
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Andrew D Johnson; Robert E Handsaker; Sara L Pulit; Marcia M Nizzari; Christopher J O'Donnell; Paul I W de Bakker Journal: Bioinformatics Date: 2008-10-30 Impact factor: 6.937
Authors: Colin A Hodgkinson; Qiaoping Yuan; Ke Xu; Pei-Hong Shen; Elizabeth Heinz; Elizabeth A Lobos; Elizabeth B Binder; Joe Cubells; Cindy L Ehlers; Joel Gelernter; John Mann; Brien Riley; Alec Roy; Boris Tabakoff; Richard D Todd; Zhifeng Zhou; David Goldman Journal: Alcohol Alcohol Date: 2008-05-12 Impact factor: 2.826
Authors: Marlene Oscar-Berman; Mary M Valmas; Kayle S Sawyer; Shalene M Kirkley; David A Gansler; Diane Merritt; Ashley Couture Journal: Neuropsychiatr Dis Treat Date: 2009-06-10 Impact factor: 2.570
Authors: Dawei Li; Hongyu Zhao; Henry R Kranzler; Ming D Li; Kevin P Jensen; Tetyana Zayats; Lindsay A Farrer; Joel Gelernter Journal: Neuropsychopharmacology Date: 2014-09-27 Impact factor: 7.853
Authors: M-R Rautiainen; T Paunio; E Repo-Tiihonen; M Virkkunen; H M Ollila; S Sulkava; O Jolanki; A Palotie; J Tiihonen Journal: Transl Psychiatry Date: 2016-09-06 Impact factor: 6.222
Authors: Xin He; Stephan J Sanders; Li Liu; Silvia De Rubeis; Elaine T Lim; James S Sutcliffe; Gerard D Schellenberg; Richard A Gibbs; Mark J Daly; Joseph D Buxbaum; Matthew W State; Bernie Devlin; Kathryn Roeder Journal: PLoS Genet Date: 2013-08-15 Impact factor: 5.917